Stoneridge Investment Partners LLC Acquires Shares of 21,789 Zoetis Inc. $ZTS

Stoneridge Investment Partners LLC acquired a new stake in Zoetis Inc. (NYSE:ZTS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 21,789 shares of the company’s stock, valued at approximately $2,741,000. Zoetis comprises approximately 1.9% of Stoneridge Investment Partners LLC’s portfolio, making the stock its 13th biggest position.

A number of other hedge funds and other institutional investors have also made changes to their positions in ZTS. RFG Advisory LLC boosted its position in Zoetis by 4.9% during the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after purchasing an additional 80 shares in the last quarter. YANKCOM Partnership boosted its position in Zoetis by 3.5% during the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after purchasing an additional 81 shares in the last quarter. Evergreen Capital Management LLC boosted its position in Zoetis by 3.3% during the third quarter. Evergreen Capital Management LLC now owns 2,696 shares of the company’s stock valued at $394,000 after purchasing an additional 85 shares in the last quarter. Beese Fulmer Investment Management Inc. boosted its position in Zoetis by 2.4% during the third quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock valued at $537,000 after purchasing an additional 85 shares in the last quarter. Finally, Quest 10 Wealth Builders Inc. raised its stake in Zoetis by 4.7% in the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after buying an additional 86 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other news, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. This trade represents a 13.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frank A. Damelio acquired 6,650 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 11,650 shares of company stock worth $886,384 over the last three months. 0.22% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

ZTS has been the subject of a number of research analyst reports. Bank of America increased their price target on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research note on Friday, February 13th. JPMorgan Chase & Co. decreased their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Citigroup initiated coverage on Zoetis in a research note on Wednesday, April 15th. They issued a “buy” rating and a $145.00 price target for the company. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday, March 10th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $137.50.

Zoetis Trading Down 1.8%

Zoetis stock opened at $74.11 on Friday. Zoetis Inc. has a one year low of $72.38 and a one year high of $172.23. The stock has a market cap of $31.07 billion, a PE ratio of 12.29, a price-to-earnings-growth ratio of 1.21 and a beta of 0.87. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The stock has a 50-day moving average of $112.28 and a two-hundred day moving average of $120.94.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter in the previous year, the business earned $1.48 earnings per share. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.91 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.